GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dezhan Healthcare Co Ltd (SZSE:000813) » Definitions » EV-to-EBIT

Dezhan Healthcare Co (SZSE:000813) EV-to-EBIT : -88.89 (As of Jun. 01, 2025)


View and export this data going back to 1998. Start your Free Trial

What is Dezhan Healthcare Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Dezhan Healthcare Co's Enterprise Value is ¥4,619.6 Mil. Dezhan Healthcare Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-52.0 Mil. Therefore, Dezhan Healthcare Co's EV-to-EBIT for today is -88.89.

The historical rank and industry rank for Dezhan Healthcare Co's EV-to-EBIT or its related term are showing as below:

SZSE:000813' s EV-to-EBIT Range Over the Past 10 Years
Min: -209.24   Med: 19.1   Max: 235.39
Current: -88.89

During the past 13 years, the highest EV-to-EBIT of Dezhan Healthcare Co was 235.39. The lowest was -209.24. And the median was 19.10.

SZSE:000813's EV-to-EBIT is ranked worse than
100% of 688 companies
in the Drug Manufacturers industry
Industry Median: 17.055 vs SZSE:000813: -88.89

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Dezhan Healthcare Co's Enterprise Value for the quarter that ended in Mar. 2025 was ¥4,662.9 Mil. Dezhan Healthcare Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-52.0 Mil. Dezhan Healthcare Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -1.11%.


Dezhan Healthcare Co EV-to-EBIT Historical Data

The historical data trend for Dezhan Healthcare Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dezhan Healthcare Co EV-to-EBIT Chart

Dezhan Healthcare Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.57 -201.38 -47.03 52.24 -97.63

Dezhan Healthcare Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.33 16.36 121.27 -97.63 -89.73

Competitive Comparison of Dezhan Healthcare Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Dezhan Healthcare Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dezhan Healthcare Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dezhan Healthcare Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dezhan Healthcare Co's EV-to-EBIT falls into.


;
;

Dezhan Healthcare Co EV-to-EBIT Calculation

Dezhan Healthcare Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4619.555/-51.968
=-88.89

Dezhan Healthcare Co's current Enterprise Value is ¥4,619.6 Mil.
Dezhan Healthcare Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-52.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dezhan Healthcare Co  (SZSE:000813) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Dezhan Healthcare Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-51.968/4662.85436
=-1.11 %

Dezhan Healthcare Co's Enterprise Value for the quarter that ended in Mar. 2025 was ¥4,662.9 Mil.
Dezhan Healthcare Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-52.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dezhan Healthcare Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Dezhan Healthcare Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Dezhan Healthcare Co Business Description

Traded in Other Exchanges
N/A
Address
No. 235 Yin Chuan Road, Xinjiang, Urumqi, CHN, 830054
Dezhan Healthcare Co Ltd's main business is drug research and development, production, and sales. The company's wholly-owned subsidiary Jialin Pharmaceuticals mainly engages in the research and development, production, and sale of cardiovascular drugs, the drugs being produced and sold including Ale (10mg), Alle (20mg), hydrochloric acid quercetine capsules, Van Le tablets type 1, Van Le tablets.
Executives
Liu Ye Executives
Zhang Yong Director
Gao Li Supervisors
Sun Ji Lu Supervisors
Wang Xiao Ping Director

Dezhan Healthcare Co Headlines

No Headlines